Roberto Bizzotto

Roberto Bizzotto

Auto-generated profile, based on publicly available information

Roberto Bizzotto

Institute of Neuroscience, National Research Council, Padova, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
EFEle Ferrannini
Ele Ferrannini
SBSimona Baldi
Simona Baldi
SFSilvia Frascerra
Silvia Frascerra
BABrenno Astiarraga
Brenno Astiarraga
THTim Heise
Tim Heise
EMElza Muscelli
Elza Muscelli
Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release. In type 2 diabetes (T2D), along with decrements in plasma glucose and insulin levels and increments in glucagon release, sodium–glucose cotransporter 2 (SGLT2) inhibitors induce stimulation of endogenous glucose production (EGP) and a suppression of tissue glucose disposal (TGD). We measured fasting and postmeal glucose fluxes in 25 subjects without diabetes using a double glucose tracer technique; in these subjects and in 66 previously reported patients with T2D, we also estimated lipolysis (from [2H5]glycerol turnover rate and circulating free fatty acids, glycerol, and triglycerides), lipid oxidation (LOx; by indirect calorimetry), and ketogenesis (from circulating β-hydroxybutyrate concentrations). In both groups, empagliflozin administration raised EGP, lowered TGD, and stimulated lipolysis, LOx, and ketogenesis. The pattern of glycosuria-induced changes was similar in subjects without diabetes and in those with T2D but quantitatively smaller in the former. With chronic (4 weeks) versus acute (first dose) drug administration, glucose flux responses were attenuated, whereas lipid responses were enhanced; in patients with T2D, fasting β-hydroxybutyrate levels rose from 246 ± 288 to 561 ± 596 µmol/L (P < 0.01). We conclude that by shunting substantial amounts of carbohydrate into urine, SGLT2-mediated glycosuria results in a progressive shift in fuel utilization toward fatty substrates. The associated hormonal milieu (lower insulin-to-glucagon ratio) favors glucose release and ketogenesis.

4 January 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
AWAgata Wesolowska-Andersen
Agata Wesolowska-Andersen
CBCaroline A. Brorsson
Caroline A. Brorsson
RBRoberto Bizzotto
Roberto Bizzotto
AMAndrea Mari
Andrea Mari
ATAndrea Tura
Andrea Tura
SBSøren Brunak
Søren Brunak
The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility may be limited if categorical representations of complex phenotypes are suboptimal.

23 October 2015 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
WAW. Alsalim
W. Alsalim
ATA. Tura
A. Tura
GPG. Pacini
G. Pacini
BOB. Omar
B. Omar
RBR. Bizzotto
R. Bizzotto
BABo Ahren
Bo Ahren

29 May 2015 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
MSMj Swat
Mj Swat
SMS Moodie
S Moodie
SWSm Wimalaratne
Sm Wimalaratne
NKNr Kristensen
Nr Kristensen
MLM Lavielle
M Lavielle
NNN Le Novère
N Le Novère
The lack of a common exchange format for mathematical models in pharmacometrics has been a long‐standing problem. Such a format has the potential to increase productivity and analysis quality, simplify the handling of complex workflows, ensure reproducibility of research, and facilitate the reuse of existing model resources. Pharmacometrics Markup Language (PharmML), currently under development by the Drug Disease Model Resources (DDMoRe) consortium, is intended to become an exchange standard in pharmacometrics by providing means to encode models, trial designs, and modeling steps.

1 September 2019 in Journal of Hepatology
Verified
Journal Article
Open access
HWHenry R. Wilman
Henry R. Wilman
CPConstantinos A. Parisinos
Constantinos A. Parisinos
NANaeimeh Atabaki-Pasdar
Naeimeh Atabaki-Pasdar
MKMatt Kelly
Matt Kelly
ETElizabeth Thomas
Elizabeth Thomas
BWBrandon Whitcher
Brandon Whitcher
Excess liver iron content is common and is linked to the risk of hepatic and extrahepatic diseases. We aimed to identify genetic variants influencing liver iron content and use genetics to understand its link to other traits and diseases. First, we performed a genome-wide association study (GWAS) in 8,289 individuals from UK Biobank, whose liver iron level had been quantified by magnetic resonance imaging, before validating our findings in an independent cohort (n = 1,513 from IMI DIRECT). Second, we used Mendelian randomisation to test the causal effects of 25 predominantly metabolic traits on liver iron content. Third, we tested phenome-wide associations between liver iron variants and 770 traits and disease outcomes. We identified 3 independent genetic variants (rs1800562 [C282Y] and rs1799945 [H63D] in HFE and rs855791 [V736A] in TMPRSS6) associated with liver iron content that reached the GWAS significance threshold (p <5 × 10-8). The 2 HFE variants account for ∼85% of all cases of hereditary haemochromatosis. Mendelian randomisation analysis provided evidence that higher central obesity plays a causal role in increased liver iron content. Phenome-wide association analysis demonstrated shared aetiopathogenic mechanisms for elevated liver iron, high blood pressure, cirrhosis, malignancies, neuropsychiatric and rheumatological conditions, while also highlighting inverse associations with anaemias, lipidaemias and ischaemic heart disease. Our study provides genetic evidence that mechanisms underlying higher liver iron content are likely systemic rather than organ specific, that higher central obesity is causally associated with higher liver iron, and that liver iron shares common aetiology with multiple metabolic and non-metabolic diseases. Excess liver iron content is common and is associated with liver diseases and metabolic diseases including diabetes, high blood pressure, and heart disease. We identified 3 genetic variants that are linked to an increased risk of developing higher liver iron content. We show that the same genetic variants are linked to higher risk of many diseases, but they may also be associated with some health advantages. Finally, we use genetic variants associated with waist-to-hip ratio as a tool to show that central obesity is causally associated with increased liver iron content.

1 February 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
WAWathik Alsalim
Wathik Alsalim
BOBilal Omar
Bilal Omar
GPGiovanni Pacini
Giovanni Pacini
RBRoberto Bizzotto
Roberto Bizzotto
AMAndrea Mari
Andrea Mari
BABo Ahrén
Bo Ahrén
Postprandial glucose homeostasis is regulated through the secretion of glucagon-like peptide 1 (GLP-1) through the stimulation of insulin secretion and inhibition of glucagon secretion. However, how these processes dynamically adapt to demands created by caloric challenges achieved during daily life is not known. The objective of the study was to explore the adaptation of incretin and islet hormones after mixed meals of increasing size in healthy subjects. Twenty-four healthy lean subjects ingested a standard breakfast after an overnight fast followed, after 4 hours, by a lunch of a different size (511, 743, and 1034 kcal) but with identical nutrient composition together with 1.5 g paracetamol. Glucose, insulin, C-peptide, glucagon, intact GLP-1, and glucose-dependent insulinotropic polypeptide (GIP) and paracetamol were measured after the meals. Area under the 180-minute curve (AUC) for insulin, C-peptide, glucagon, GLP-1, and GIP and model-derived β-cell function and paracetamol appearance were calculated. Glucose profiles were similar after the two larger meals, whereas after the smaller meal, there was a postpeak reduction below baseline to a nadir of 3.8 ± 0.1 mmol/L after 75 minutes (P < .001). The AUC for GLP-1, GIP, insulin, and C-peptide were significantly higher by increasing the caloric load as was β-cell sensitivity to glucose. In contrast, the AUC glucagon was the same for all three meals, although there was an increase in glucagon after the postpeak glucose reduction in the smaller meal. The 0- to 20-minute paracetamol appearance was increased by increasing meal size. Mixed lunch meals of increasing size elicit a caloric-dependent insulin response due to increased β-cell secretion achieved by increased GIP and GLP-1 levels. The adaptation at larger meals results in identical glucose excursions, whereas after a lower caloric lunch, the insulin response is high, resulting in a postpeak suppression of glucose below baseline.